Skip to main content
Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.900
-0.200 (-4.88%)
At close: Apr 28, 2026, 4:00 PM EDT
3.817
-0.083 (-2.13%)
After-hours: Apr 28, 2026, 4:27 PM EDT

Orchestra BioMed Holdings Revenue

In the year 2025, Orchestra BioMed Holdings had annual revenue of $33.48M with 1,169.22% growth. Orchestra BioMed Holdings had revenue of $30.92M in the quarter ending December 31, 2025, with 12,120.16% growth.

Revenue (ttm)
$33.48M
Revenue Growth
+1,169.22%
P/S Ratio
6.78
Revenue / Employee
$389,326
Employees
86
Market Cap
228.23M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202533.48M30.84M1,169.22%
Dec 31, 20242.64M-122.00K-4.42%
Dec 31, 20232.76M-773.00K-21.88%
Dec 31, 20223.53M4.32M-551.79%
Dec 31, 2021-782.00K-6.49M-113.71%
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Arcturus Therapeutics Holdings 82.03M
Codexis 70.39M
Fennec Pharmaceuticals 44.64M
Sol-Gel Technologies 19.39M
Adagene 7.67M
Camp4 Therapeutics 3.50M
Milestone Pharmaceuticals 1.55M
Artiva Biotherapeutics 251.00K
Revenue Rankings

OBIO News

More News